Study shows drug combination improves outcome for advanced non-small cell lung cancer
Sunday, May 31, 2009 - 10:08
in Health & Medicine
A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III 'ATLAS' trial were presented today by Dr Vincent Miller of Memorial Sloan-Kettering Cancer Centre (MSKCC) at the American Society of Clinical Oncology Annual Meeting...
Read the whole article on Science Centric
More from Science Centric
Related
- Study shows drug combination improves outcome for advanced non-small cell lung cancerSat, 30 May 2009, 11:29:37 EDT
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT
- African American lung cancer patients may have different response to new cancer-fighting drugsWed, 7 Oct 2009, 18:11:47 EDT
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patientsSat, 1 Aug 2009, 15:37:16 EDT